8-K: Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

Entera Bio reports its full year 2024 financial results, highlighting key data read-outs and advancements in its oral peptide programs.

Summary

• Entera Bio announced its financial results for the year ended December 31, 2024.
• The company highlighted key data read-outs and advancements in its oral peptide PTH(1-34), GLP1/Glucagon, and GLP2 tablet programs.
• Entera's cash and cash equivalents as of December 31, 2024, were $8.7 million.
• As of March 28, 2025, cash and cash equivalents increased to $21 million due to investments from existing and new institutional shareholders and OPKO.
• The company expects its cash to fund operations into the third quarter of 2026.
• Research and development expenses for 2024 were $4.5 million, consistent with 2023.
• General and administrative expenses for 2024 were $5.1 million, compared to $4.4 million in 2023.
• The net loss for 2024 was $9.5 million, or $0.25 per ordinary share, compared to $8.9 million, or $0.31 per ordinary share, in 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the company's progress in its clinical programs, collaboration with OPKO Health, and strengthened balance sheet. However, the net loss and reliance on future funding temper the overall sentiment.

Positives

• Entera Bio has made significant progress in its oral peptide programs, including EB613 for osteoporosis and GLP-1/glucagon for obesity.
• The company has strengthened its balance sheet with $21 million in cash and cash equivalents as of March 28, 2025.
• Entera Bio has a collaboration and license agreement with OPKO Health for the development of oral GLP-1/glucagon and GLP-2 tablet programs.
• The FDA is reviewing the SABRE project, which could accelerate the development of new osteoporosis drugs.
• Entera's cash position is expected to fund operations into the third quarter of 2026.

Negatives

• Entera Bio reported a net loss of $9.5 million for the year ended December 31, 2024.
• The company's cash and cash equivalents were $8.7 million as of December 31, 2024, which increased to $21 million by March 28, 2025, through additional funding.
• The company is operating at a loss and is reliant on further funding to continue operations.

Risks

• The company's future success depends on the outcome of clinical trials and regulatory approvals.
• Entera Bio is reliant on third parties, including OPKO Health, for the development and commercialization of its product candidates.
• The company's ability to continue as a going concern depends on access to sources of liquidity.
• There are risks associated with changes in the interpretation of clinical data and regulatory timelines.
• The company faces competition from other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, and metabolic conditions.

Future Outlook

Entera Bio plans to continue its mission to add value in 2025, with a focus on execution, including initiating a pivotal Phase 3 study of EB613 and filing an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) later this year for the Oral OXM program.

Management Comments

• Miranda Toledano, Chief Executive Officer of Entera, stated that 2024 was a truly transformational year for Entera.
• Miranda Toledano expressed gratitude to the core team, global advisors, shareholders, and collaborators for their commitment and support.
• Miranda Toledano emphasized the company's dedication to developing EB613 for the majority of the estimated 200 million women with osteoporosis who wish to preserve their bone health.

Industry Context

Entera Bio is focused on developing oral peptide and protein replacement therapies, which could transform the standard of care for diseases like osteoporosis, obesity, and short bowel syndrome. The company's N-Tab platform aims to provide oral alternatives to injectable therapies, addressing unmet medical needs and improving patient compliance.

Comparison to Industry Standards

• The company compares the SABRE project to prior initiatives that qualified LDL cholesterol as a surrogate marker for CV outcomes and HBA1C as a surrogate for the risk of future diabetes complications.
• The company compares the plasma concentrations and half-life of its oral OXM to semaglutide (Rybelsus), the only approved oral GLP-1 analog.
• The company compares the plasma levels achieved with its oral GLP-2 tablet to therapeutic plasma concentrations reported for subcutaneously administered teduglutide (Gattex).

Stakeholder Impact

• Shareholders: The announcement provides updates on the company's financial performance and clinical development programs, which could impact shareholder value.
• Employees: The company's progress and financial stability could impact employee morale and job security.
• Patients: The development of oral peptide therapies could provide new treatment options for patients with osteoporosis, obesity, hypoparathyroidism, and short bowel syndrome.
• Collaborators: The collaboration with OPKO Health is important for the development of oral GLP-1/glucagon and GLP-2 tablet programs.

Next Steps

• Initiate a Phase 3 registrational study for EB613.
• File an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) later this year for the Oral OXM program.
• Determine next steps for the oral GLP-2 program in collaboration with OPKO Health.
• Continue collaboration with a third party on the oral tablet development of another PTH replacement treatment for hypoparathyroidism.

Key Dates

Keywords

Entera Bio, EB613, Osteoporosis, Oral Peptide, GLP-1, Glucagon, GLP-2, OPKO Health, Financial Results, N-Tab Platform